Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.8 EUR | -17.65% |
|
-.--% | -.--% |
05-15 | STRATA Skin Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-15 | Transcript : STRATA Skin Sciences, Inc., Q1 2024 Earnings Call, May 15, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 10.59M | - | ||
+0.91% | 204B | B | ||
+3.74% | 178B | B- | ||
+28.89% | 156B | B- | ||
+31.66% | 113B | A- | ||
+1.18% | 64.26B | A- | ||
+19.45% | 54.98B | B+ | ||
-3.44% | 47.44B | B+ | ||
-9.28% | 36.7B | A | ||
-0.10% | 34.84B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SSKN Stock
- E2O Stock
- Ratings STRATA Skin Sciences, Inc.